| |
|
|
|
|
|
 |
| |
|
À̺ÎÄðÁ¤ IBUCOOL TAB.[Allylisopropyl acetylurea , Caffeine anhydrous , Ibuprofen]
|
|
ÀϹÝÀǾàǰ | ¹Ì»ý»ê
|
|
|
| |
 |
¾Ë¸²: |
µå·°ÀÎÆ÷¿¡¼´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
|
|
|
 | Çã°¡Á¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇÑ±Ý¾× |
ºñ±Þ¿©
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁ¶È¸]
|
| ºü¸¥Á¶È¸ |
|
| Á¦Ç°¼º»ó |
¹é»öÀÇ ¿øÇü Çʸ§ÄÚÆÃÁ¦ [Á¦ÇüÁ¤º¸ È®ÀÎ] |
| Æ÷À塤À¯Åë´ÜÀ§ |
12's |
| È¿´ÉÈ¿°ú |
[ÀûÀÀÁõ º° °Ë»ö]
µÎÅë, Ä¡Åë, »ý¸®Åë, ÀÎÈÄÅë, °üÀýÅë, ±ÙÀ°Åë, ½Å°æÅë, ¿äÅë, °ßÅë, ¹ßÄ¡ÈÄÀÇ µ¿Åë, Ÿ¹ÚÅë, ±ÍÀÇÅëÁõ, °ñÀýÅë, ¿°ÁÂÅë, ¿Ü»óÅëÀÇ ÁøÅë, ¿ÀÇÑ, ¹ß¿½ÃÀÇ ÇØ¿.
|
| ¿ë¹ý¿ë·® |
* Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.
[󹿾à¾î]
<ol>15¼¼ ÀÌ»ó 1ȸ 2Á¤, 1ÀÏ 3ȸ º¹¿ëÇÑ´Ù.
°øº¹À» ÇÇÇÏ¿© º¹¿ëÇÏ¸ç º¹¿ë°£°ÝÀº 4½Ã°£ ÀÌ»óÀÌ µÇµµ·Ï ÇÑ´Ù.
|
| ÁÖ¿ä¾à¹° »óÈ£ÀÛ¿ë |
[Á¶È¸]
|
| ±Ý±â |
- º»Á¦¿¡ ÀÇÇÑ °ú¹ÎÁõ»ó(¹ßÁø.¹ßÀû,°¡·Á¿ò, ºÎÁ¾µî)À» ÀÏÀ¸Å² ÀûÀÌ ÀÖ´Â »ç¶÷
- º»Á¦ ¶Ç´Â ´Ù¸¥ ÇØ¿ÁøÅë¾à,°¨±â¾àÀ» º¹¿ëÇÏ¿© õ½ÄÀ» ÀÏÀ¸Å² ÀûÀÌ ÀÖ´Â »ç¶÷
- º»Á¦¸¦ º¹¿ëÇÏ´Â µ¿¾ÈÀº ´ÙÀ½ ¾î´À ÀǾàǰµµ º¹¿ëÇÏÁö ¸» °Í.
´Ù¸¥ ÇØ¿ÁøÅë¾à,°¨±â¾à,ÁøÁ¤¾à
- º¹¿ë ÈÄ Á¹À½ÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î ÀÚµ¿Â÷ ¶Ç´Â ±â°è·ùÀÇ Á¶ÀÛÀ» ÇÏÁö ¸» °Í.
- º¹¿ë ½Ã¿¡´Â À½ÁÖ¸¦ ÇÏÁö ¸» °Í.
- Àå±â ¿¬¿ëÀ» ÇÏÁö ¸» °Í.
|
| ½ÅÁßÅõ¿© |
- ÀÇ»ç ¶Ç´Â Ä¡°úÀÇ»çÀÇ Ä¡·á¸¦ ¹Þ°í ÀÖ´Â »ç¶÷
- ÀӺΠ¶Ç´Â ÀÓ½ÅÇϰí ÀÖÀ» °¡´É¼ºÀÌ ÀÖ´Â »ç¶÷
- ¼öÀ¯ºÎ
- °í·ÉÀÚ
- º»ÀÎ ¶Ç´Â °¡Á·ÀÌ ¾Ë·¹¸£±â üÁúÀÎ »ç¶÷
- ¾à¿¡ ÀÇÇØ ¾Ë·¹¸£±â Áõ»óÀ» ÀÏÀ¸Å² ÀûÀÌ ÀÖ´Â »ç¶÷
- ½ÉÀ庴, ½ÅÀ庴, °£À庴, Àü½Å¼º È«¹Ý¼º ·çǪ½º, È¥ÇÕ¼º °áÇÕÁ¶Á÷ÁúȯÀÇ ÁúȯÀ» ¹ÞÀº °æ¿ì
- À§.½ÊÀÌÁöÀå±Ë¾ç, ±Ë¾ç¼º´ëÀå¿°, Å©·Ð¾¾º´ Áúȯ¿¡ °É¸° ÀûÀÌ ÀÖ´Â »ç¶÷
|
| ÀÌ»ó¹ÝÀÀ |
- º¹¿ëÈÄ ´ÙÀ½ÀÇ Áõ»óÀÌ ³ªÅ¸³ª´Â °æ¿ì Áï½Ã º¹¿ëÀ» ÁßÁöÇϰí ÀÌ ¼³¸í¼º¸£ °¡Áö°í ÀÇ»ç, Ä¡°úÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇÒ °Í.
- ÇǺÎ; ¹ßÁø, ¹ßÀû, °¡·Á¿ò, ºÎÁ¾ÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
- ¼Òȱâ; ¿À½É, ±¸Åä, ½Ä¿åºÎÁø, À§Åë, À§ºÎºÒÄè°¨, ±¸³»¿°µî ÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
- Á¤½Å½Å°æ°è; Çö±âÁõÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
- ±âŸ; ´«ÀÌ Ä§Ä§ÇÔ(È帲), À̸íµîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
- 5-6ȸ º¹¿ëÇØµµ Áõ»óÀÌ ÁÁ¾ÆÁöÁö ¾Ê´Â °æ¿ì
- º¯ºñ, ¼³»çÀÇ Áõ»óÀÌ ³ªÅ¸³ ÀûÀÌ ÀÖÀ¸¸ç ÀÌ·±ÇÑ Áõ»óÀÌ °è¼Ó ¶Ç´Â Áõ°µÇ´Â °æ¿ì
- µå¹°°Ô ´ÙÀ½ÀÇ ÁßøµÈ Áõ»óÀÌ ÀϾ ¼ö ÀÖÀ¸¸ç, ÀÌ·¯ÇÑ °æ¿ìÀº Áï½Ã ÀÇ»çÀÇ Áø·á¸¦ ¹ÞÀ» °Í.
- ¼ï(¾Æ³ªÇʶô½Ã½º); º¹¿ëÈÄ ¹Ù·Î ´ã¸¶Áø, ºÎÁ¾, °¡½¿ÀÌ ´ä´äÇÔ µî°ú ÇÔ²² ¾È»öÀÌ Ã¢¹éÇϰí, ¼öÁ·ÀÌ Â÷°í, ½ÄÀº ¶¡, ¼ûÀÌ °¡»Û Áõ»óÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
- ÇǺÎÁ¡¸·¾ÈÁõÈıº, Áßµ¶¼º Ç¥ÇDZ«»çÁõ; °í¿À» ¼ö¹ÝÇϰí, ¹ßÁø, ¹ßÀû, È»ó ¸ð¾çÀÇ ¹°Áý µî ½É
ÇÑ Áõ»óÀÌ Àü½ÅÀÇ ÇǺÎ, ÀÔÀ̳ª ´« Á¡¸·¿¡ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
- °£±â´ÉÀåÇØ; Àü½ÅÀÇ ³ª¸¥ÇÔ, Ȳ´Þ(ÇǺγª ÈòÀÚÀ§°¡ Ȳ»öÀ¸·Î µÊ)µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
- ½ÅÀåÇØ; ´¢·®ÀÌ °¨¼ÒÇϰí Àü½ÅÀÇ ºÎÁ¾À̳ª ¿©±â¿¡ ¼ö¹ÝµÇ¾î ¼ûÀÌ °¡»Ú°í, ³ª¸¥ÇÔ, ¿À½É, ±¸Åä, Ç÷´¢, ´Ü¹é´¢ µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
- ¹«±Õ¼º ¼ö¸·¿°; ¸ñ´ú¹ÌÀÇ ¶¯±èÀ» ¼ö¹ÝÇÏ´Â ½ÉÇÑ µÎÅë, ¹ß¿, ¿À½É, ±¸Åä µîÀÇ Áõ»óÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù. (ÀÌ·¯ÇÑ Áõ»óÀº ƯÈ÷ Àü½Å¼º È«¹Ý¼º ·çǪ½º¶Ç´Â È¥ÇÕ¼º °áÇÕÁ¶Á÷ÁúȯÀÇ Ä¡·á¸¦ ¹Þ°í ÀÖ´Â »ç¶÷¿¡°Ô¼ ¸¹ÀÌ º¸°íµÇ°í ÀÖ´Ù.
- õ½ÄÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
|
| Off-label Usage |
[Á¶È¸]
|
| Related FDA Approved Drug |
|
|
|
 | Á¤º¸¿ä¾à |
|
|
|
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
|
|
 | ÄÚµå ¹× ºÐ·ùÁ¤º¸ |
|
|
| |
|
 | Á¦Ç°Á¤º¸ |
|
|
|
|
 | º¹¾àÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| LACTmed ¹Ù·Î°¡±â |
[¹Ù·Î°¡±â]
|
| ¾à¸®ÀÛ¿ë |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| ÀӺο¡´ëÇÑÅõ¿© |
| * |
ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù.
|
|
|   |
 FDA : Dµî±Þ
(ibuprofen ÀӽŠ3±â ¶Ç´Â ¸»±â¿¡ Åõ¿©½Ã )
|
|
| * |
»ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
|
| * |
¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
|
|
|
½ÅÀå¾Ö, °£Àå¾Ö½Ã ¿ë·®Á¶Àý |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| Pharmacokinetics |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸ |
[º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸]
|
| º¹¾à¶óº§ |
| À̹ÌÁö |
º¹¾à¼³¸í |
 |
¼úÀ̳ª ¾ËÄݼº À½·á¸¦ ¸¶½ÃÁö ¸»°Í |
|
 |
º¯ºñ°¡ »ý±æ¼ö ÀÖ½À´Ï´Ù. |
|
 |
¾îÁö·¯¿òÀÌ ÀÖÀ»¼ö ÀÖ½À´Ï´Ù. |
|
|
| * |
º¹¾àÀ̹ÌÁö´Â ¸ðµç º¹¾àÁöµµ »çÇ×À» Ç¥½ÃÇѰÍÀº ¾Æ´Ï¸ç, Ãß°¡ÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ°Å³ª ¼öÁ¤µÉ ¼ö ÀÖ½À´Ï´Ù. |
| * |
º¹¾àÀ̹ÌÁöÀÇ Ç¥½Ã¿©ºÎ´Â ½ÇÁ¦ ¾à¹°º¹¿ë½Ã Á߿䵵¿¡ µû¸¥°ÍÀº ¾Æ´Ï¸ç ´Ü¼øÈ÷ Çã°¡Á¤º¸»ó Ű¿öµå¸¦ ±âÁØÀ¸·Î µî·ÏµÇ¾ú½À´Ï´Ù. |
| * |
±ÍÇϰ¡ º¹¾àÀ̹ÌÁö Á¤º¸¸¦ ½Å·ÚÇÔÀº ÀüÀûÀ¸·Î ±ÍÇÏÀÇ Ã¥ÀÓÀÔ´Ï´Ù. µå·°ÀÎÆ÷´Â ÀÌ¿¡ ´ëÇÑ ¾î¶°ÇÑ º¸Áõµµ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
| º¸°ü»ó ÁÖÀÇ |
|
| Á¶Á¦½Ã ÁÖÀÇ |
|
|
|
 | ½É»çÁ¤º¸ |
|
|
|
|
 | ÇмúÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| DUR (ÀǾàǰ»ç¿ëÆò°¡) |
º´¿ë±Ý±â :
°í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
°í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
|
| µ¶¼ºÁ¤º¸ |
Ibuprofen¿¡ ´ëÇÑ µ¶¼ºÁ¤º¸ : Á¤º¸º¸±â
Urea¿¡ ´ëÇÑ µ¶¼ºÁ¤º¸ : Á¤º¸º¸±â
Ãâó: ±¹¸³µ¶¼º°úÇпø µ¶¼º¹°ÁúÁ¤º¸DB : http://www.nitr.go.kr/nitr/contents/m134200/view.do |
| Mechanism of Action |
Caffeine¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Caffeine stimulates medullary, vagal, vasomotor, and respiratory centers, promoting bradycardia, vasoconstriction, and increased respiratory rate. This action was previously believed to be due primarily to increased intracellular cyclic 3¡Ç,5¡Ç-adenosine monophosphate (cyclic AMP) following inhibition of phosphodiesterase, the enzyme that degrades cyclic AMP. It is now thought that xanthines such as caffeine act as agonists at adenosine-receptors within the plasma membrane of virtually every cell. As adenosine acts as an autocoid, inhibiting the release of neurotransmitters from presynaptic sites but augmenting the actions of norepinephrine or angiotensin, antagonism of adenosine receptors promotes neurotransmitter release. This explains the stimulatory effects of caffeine. Blockade of the adenosine A1 receptor in the heart leads to the accelerated, pronounced "pounding" of the heart upon caffeine intake.
Ibuprofen¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ The exact mechanisms of action of Ibuprofen is unknown. Its antiinflammatory effects are believed to be due to inhibition of both cylooxygenase-1 (COX-1) and cylooxygenase-2 (COX-2) which leads to the inhibition of prostaglandin synthesis, and results in the inhibition of prostaglandin synthesis. Antipyretic effects may be due to action on the hypothalamus, resulting in an increased peripheral blood flow, vasodilation, and subsequent heat dissipation.
|
| Pharmacology |
Caffeine¿¡ ´ëÇÑ Pharmacology Á¤º¸ Caffeine, a naturally occurring xanthine derivative like theobromine and the bronchodilator theophylline, is used as a CNS stimulant, mild diuretic, and respiratory stimulant (in neonates with apnea of prematurity). Often combined with analgesics or with ergot alkaloids, caffeine is used to treat migraine and other headache types. Over the counter, caffeine is available to treat drowsiness or mild water-weight gain.
Ibuprofen¿¡ ´ëÇÑ Pharmacology Á¤º¸ Ibuprofen is a nonsteroidal antiinflammatory drug (NSAID) with analgesic and antipyretic properties. Ibuprofen has pharmacologic actions similar to those of other prototypical NSAIAs, that is thought to be associated with the inhibition of prostaglandin synthesis. Ibuprofen is used to treat rheumatoid arthritis, osteoarthritis, dysmenorrhea, and to alleviate moderate pain.
|
| Metabolism |
Caffeine¿¡ ´ëÇÑ Metabolism Á¤º¸ # Phase_1_Metabolizing_Enzyme:Cytochrome P450 1A2 (CYP1A2)
Ibuprofen¿¡ ´ëÇÑ Metabolism Á¤º¸ # Phase_1_Metabolizing_Enzyme:Cytochrome P450 2C9 (CYP2C9)Monoamine oxidase type B (MAO-B)
|
| Protein Binding |
Caffeine¿¡ ´ëÇÑ ´Ü¹é°áÇÕ Á¤º¸ Low (25 to 36%).
Ibuprofen¿¡ ´ëÇÑ ´Ü¹é°áÇÕ Á¤º¸ 99%
|
| Half-life |
Caffeine¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ 3 to 7 hours in adults, 65 to 130 hours in neonates
Ibuprofen¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ 1.8-2.0 hours
|
| Absorption |
Caffeine¿¡ ´ëÇÑ Absorption Á¤º¸ Readily absorbed after oral or parenteral administration. The peak plasma level for caffeine range from 6-10mg/L and the mean time to reach peak concentration ranged from 30 minutes to 2 hours.
Ibuprofen¿¡ ´ëÇÑ Absorption Á¤º¸ rapidly absorbed
|
| Pharmacokinetics |
IbuprofenÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- ÁøÅëÈ¿°ú ¹ßÇö½Ã°£ : 30-60ºÐ
- ÀÛ¿ëÁö¼Ó½Ã°£ : 4-6 ½Ã°£
- Ç׿°È¿°ú ¹ßÇö½Ã°£ : 7ÀϱîÁö
- ÃÖ´ë Ç׿°È¿°ú ¹ßÇö½Ã°£ : 1-2ÁÖ
- Èí¼ö : °æ±¸ : ½Å¼ÓÇÏ°Ô Èí¼öµÊ (85%)
- ´Ü¹é°áÇÕ : 90-99%
- ´ë»ç : °£¿¡¼ »êÈ´ë»ç
- ¹Ý°¨±â : 2-4 ½Ã°£ (¸»±â ½ÅÁúȯ¿¡¼µµ ¹Ý°¨±â´Â º¯ÈÇÏÁö ¾ÊÀ½)
- Ç÷ÁßÃÖ°í³óµµ µµ´Þ½Ã°£ : 1-2 ½Ã°£ À̳»
- ¼Ò½Ç : ½Å¹è¼³(¹Ìº¯Èü·Î´Â 1% ¹Ì¸¸), ÀϺΠ´ãÁó¹è¼³µµ ÀϾ
Caffeine anhydrousÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- Èí¼ö : °æ±¸ : ½Å¼ÓÇϰÔ, ¿ÏÀüÈ÷ Èí¼öµÊ (99%)
- ºÐÆ÷ : ¸ðµç ü¾×¿¡ ºÐÆ÷Çϸç, ³úÇ÷°üÀ庮, ŹÝÀ» Åë°úÇϰí, À¯ÁóÀ¸·Îµµ ºÐºñµÊ
- ºÐÆ÷¿ëÀû :
- ½Å»ý¾Æ : 0.92 L/kg
- ¼ºÀÎ : 0.58 L/kg
- ´Ü¹é°áÇÕ : 15-35%
- ´ë»ç : ¼ºÀÎ : °ÅÀÇ ´ëºÎºÐÀÌ °£¿¡¼ ´ë»çµÇ¸ç, Å»¸ÞƿȵǾî paraxanthine (72%), theobromine (20%), theophylline (8%)À¸·Î ´ë»çµÊ
- ¹Ý°¨±â :
- ¹Ì¼÷¾Æ : 65-103 ½Ã°£
- ¿Ï¼÷¾Æ : 82½Ã°£
- 3-4°³¿ù ¿µ¾Æ : 14.4 ½Ã°£
- 5-6°³¿ù ¿µ¾Æ : 2.6 ½Ã°£
- ¼ºÀÎ : 3-7.5 ½Ã°£ (Æò±Õ 4.9 ½Ã°£)
- ÀӽźΠ: 18½Ã°£±îÁö
- Ç÷ÁßÃÖ°í³óµµ µµ´Þ½Ã°£ : 15-45ºÐ
- ¼Ò½Ç :
- ¼ºÀÎ : ¹Ìº¯Èü·Î ½Å¹è¼³µÇ´Â ¾çÀº 0.5-3.5%
- ½Å»ý¾Æ : °ÅÀÇ ´ëºÎºÐ ¹Ìº¯Èü·Î ½Å¹è¼³µÊ
|
| Biotransformation |
Caffeine¿¡ ´ëÇÑ Biotransformation Á¤º¸ Hepatic cytochrome P450 1A2 (CYP 1A2) is involved in caffeine biotransformation. About 80% of a dose of caffeine is metabolized to paraxanthine (1,7-dimethylxanthine), 10% to theobromine (3,7-dimethylxanthine), and 4% to theophylline (1,3-dimethylxanthine).
Ibuprofen¿¡ ´ëÇÑ Biotransformation Á¤º¸ Hepatic
|
| Toxicity |
Caffeine¿¡ ´ëÇÑ Toxicity Á¤º¸ LD50=127 mg/kg (orally in mice)
Ibuprofen¿¡ ´ëÇÑ Toxicity Á¤º¸ Abdominal pain, breathing difficulties, coma, drowsiness, headache, irregular heartbeat, kidney failure, low blood pressure, nausea, ringing in the ears, seizures, sluggishness, vomiting; LD50=1255mg/kg(orally in mice)
|
| Drug Interactions |
Caffeine¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Not Available
Ibuprofen¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Acebutolol Risk of inhibition of renal prostaglandinsAtenolol Risk of inhibition of renal prostaglandinsBetaxolol Risk of inhibition of renal prostaglandinsBevantolol Risk of inhibition of renal prostaglandinsBisoprolol Risk of inhibition of renal prostaglandinsCarteolol Risk of inhibition of renal prostaglandinsCarvedilol Risk of inhibition of renal prostaglandinsEsmolol Risk of inhibition of renal prostaglandinsLabetalol Risk of inhibition of renal prostaglandinsNadolol Risk of inhibition of renal prostaglandinsMetoprolol Risk of inhibition of renal prostaglandinsOxprenolol Risk of inhibition of renal prostaglandinsPenbutolol Risk of inhibition of renal prostaglandinsPindolol Risk of inhibition of renal prostaglandinsPractolol Risk of inhibition of renal prostaglandinsPropranolol Risk of inhibition of renal prostaglandinsSotalol Risk of inhibition of renal prostaglandinsTimolol Risk of inhibition of renal prostaglandinsWarfarin The NSAID increases the anticoagulant effectAcenocoumarol The NSAID increases the anticoagulant effectDicumarol The NSAID increases the anticoagulant effectAnisindione The NSAID increases the anticoagulant effectEthacrynic acid The NSAID decreases the diuretic and antihypertensive effect of the loop diureticFurosemide The NSAID decreases the diuretic and antihypertensive effect of the loop diureticTorasemide The NSAID decreases the diuretic and antihypertensive effect of the loop diureticBumetanide The NSAID decreases the diuretic and antihypertensive effect of the loop diureticAspirin Ibuprofen reduces ASA cardioprotective effectsMethotrexate The NSAID increases the effect and toxicity of methotrexateAlendronate Increased risk of gastric toxicityCyclosporine Monitor for nephrotoxicityLithium The NSAID increases serum levels of lithium
|
CYP450 Drug Interaction |
[CYP450 TableÁ÷Á¢Á¶È¸] Ibuprofen¿¡ ´ëÇÑ P450 table
SUBSTRATES
CYP 2C9
NSAIDs:
diclofenac
**ibuprofen**
piroxicam
Oral Hypoglycemic Agents:
tolbutamide
glipizide
Angiotensin II Blockers:
NOT candesartan
irbesartan
losartan
NOT valsartan
celecoxib
fluvastatin naproxen
phenytoin
sulfamethoxazole
tamoxifen
tolbutamide
torsemide
warfarin
INHIBITORS
CYP 2C9
amiodarone
fluconazole
isoniazid
INDUCERS
CYP 2C9
rifampin
secobarbital
|
| Food Interaction |
Ibuprofen¿¡ ´ëÇÑ Food Interaction Á¤º¸ Avoid alcohol.Take with food to reduce irritation.
|
| Drug Target |
[Drug Target]
|
| SNP Á¤º¸ |
Name:Caffeine (DB00201)
Interacting Gene/Enzyme:Cytochrome P450 1A2 (Gene symbol = CYP1A2) Swissprot P05177
SNP(s):rs762551 (C allele)
Effect:Myocardial infarction
Reference(s):Cornelis MC, El-Sohemy A, Kabagambe EK, Campos H: Coffee, CYP1A2 genotype, and risk of myocardial infarction. JAMA. 2006 Mar 8;295(10):1135-41. [PubMed]
|
| Description |
Caffeine¿¡ ´ëÇÑ Description Á¤º¸ A methylxanthine naturally occurring in some beverages and also used as a pharmacological agent. Caffeine&
Ibuprofen¿¡ ´ëÇÑ Description Á¤º¸ A nonsteroidal anti-inflammatory agent with analgesic properties used in the therapy of rheumatism and arthritis. [PubChem]
|
| Dosage Form |
Caffeine¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Capsule OralElixir OralLiquid OralPill OralSolution OralSolution / drops OralSuppository RectalSuspension OralSyrup OralTablet OralTablet, extended release Oral
Ibuprofen¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Capsule OralSuspension OralTablet OralTablet, chewable Oral
|
| Drug Category |
Caffeine¿¡ ´ëÇÑ Drug_Category Á¤º¸ Anorexigenic AgentsCentral Nervous System StimulantsPhosphodiesterase Inhibitors
Ibuprofen¿¡ ´ëÇÑ Drug_Category Á¤º¸ AnalgesicsAnalgesics, Non-NarcoticAnti-Inflammatory Agents, Non-SteroidalAnti-inflammatory AgentsCyclooxygenase InhibitorsNonsteroidal Antiinflammatory Agents (NSAIDs)
|
| Smiles String Canonical |
Caffeine¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CN1C=NC2=C1C(=O)N(C)C(=O)N2C
Ibuprofen¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CC(C)CC1=CC=C(C=C1)C(C)C(O)=O
|
| Smiles String Isomeric |
Caffeine¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ CN1C=NC2=C1C(=O)N(C)C(=O)N2C
Ibuprofen¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ CC(C)CC1=CC=C(C=C1)[C@@H](C)C(O)=O
|
| InChI Identifier |
Caffeine¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C8H10N4O2/c1-10-4-9-6-5(10)7(13)12(3)8(14)11(6)2/h4H,1-3H3
Ibuprofen¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C13H18O2/c1-9(2)8-11-4-6-12(7-5-11)10(3)13(14)15/h4-7,9-10H,8H2,1-3H3,(H,14,15)/f/h14H
|
| Chemical IUPAC Name |
Caffeine¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ 1,3,7-trimethylpurine-2,6-dione
Ibuprofen¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ 2-[4-(2-methylpropyl)phenyl]propanoic acid
|
| Drug-Induced Toxicity Related Proteins |
CAFFEINE ÀÇ Drug-Induced Toxicity Related ProteinÁ¤º¸ Replated Protein:Metallothionein Drug:caffeine Toxicity:hepatotoxicity. [¹Ù·Î°¡±â] IBUPROFEN ÀÇ Drug-Induced Toxicity Related ProteinÁ¤º¸ Replated Protein:Myeloperoxidase Drug:ibuprofen Toxicity:increase the incidence of ventricular fibrillation. [¹Ù·Î°¡±â] Replated Protein:Myeloperoxidase Drug:ibuprofen Toxicity:increase the incidence of haemorrhagic infarction. [¹Ù·Î°¡±â] Replated Protein:Arylamine N-acetyltransferase 2 Drug:ibuprofen Toxicity:ibuprofen inhibition. [¹Ù·Î°¡±â] UREA ÀÇ Drug-Induced Toxicity Related ProteinÁ¤º¸ Replated Protein:Parathyroid hormone Drug:urea Toxicity:chronic renal failure. [¹Ù·Î°¡±â]
|
|
|
 | »ç¿ëÀÚÄÁÅÙÃ÷ |
|
|
|
|
|
-
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2015-01-14
-
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
|
|
¾Ë¸² |
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù. |
|
°æ°í |
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
|
|
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
|
|
|
|